1-1 of 1
Philip Czerniak
Close
Sort by
Journal Articles

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Eduardo Huarte, PhD, Michael Peel, PhD, Philip Dube, PhD, Lynn Stephens, Becky Stewart, Brian Long, Philip Czerniak, Julian Oliver, PhD, Paul Smith, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139805
Published: 2020